PVLA · Insider Trading
Palvella Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by PVLA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-23 | Kathleen Goin | Chief Operating Officer | MIXED | — | −$502.35K |
| 2026-10-14 | George M Jenkins | Director | Sell | −27,500 | −$3.58M |
| 2026-09-18 | Kathleen Goin | Chief Operating Officer | MIXED | — | −$620.04K |
| 2026-09-15 | George M Jenkins | Director | Sell | −27,500 | −$4.17M |
| 2026-09-04 | Christopher P Kiritsy | Director | MIXED | — | −$9.33K |
| 2026-08-20 | Kathleen Goin | Chief Operating Officer | MIXED | — | −$619.91K |
| 2026-07-17 | Kathleen Goin | Chief Operating Officer | MIXED | — | −$607.31K |
| 2026-07-01 | Matthew Pauls | Director | A | +6,000 deriv. | — |
| 2026-06-22 | Kathleen Goin | Chief Operating Officer | MIXED | — | −$441.49K |
| 2026-06-16 | Matthew E Korenberg | CFO, Treasurer | M | +1,000 | +$13.60K |
| 2026-06-12 | George M Jenkins | Director | A | +3,000 deriv. | — |
| 2026-06-12 | Todd C Davis | Director | A | +3,000 deriv. | — |
| 2026-06-12 | Elaine J Heron | Director | A | +3,000 deriv. | — |
| 2026-06-12 | Christopher P Kiritsy | Director | A | +3,000 deriv. | — |
| 2026-06-12 | Tadd S. Wessel | Director | A | +3,000 deriv. | — |
| 2026-06-12 | John Doux | Director | A | +3,000 deriv. | — |
| 2026-05-22 | Kathleen Goin | Chief Operating Officer | MIXED | — | −$440.75K |
| 2026-04-17 | Kathleen Goin | Chief Operating Officer | MIXED | — | −$512.52K |
| 2026-04-15 | John Doux | Director | A | +6,000 deriv. | — |
| 2026-04-01 | George M Jenkins | Director | Buy | +445 | +$49.97K |
| 2026-03-20 | Kathleen Goin | Chief Operating Officer | MIXED | — | −$472.73K |
| 2026-03-02 | George M Jenkins | Director | Buy | +4,000 | +$500.00K |
| 2026-03-02 | Elaine J Heron | Director | Buy | +2,400 | +$300.00K |
| 2026-02-20 | Kathleen Goin | Chief Operating Officer | MIXED | — | −$306.68K |
| 2026-02-09 | Ashley Hartmann Kline | Chief Commercial Officer | A | +38,517 deriv. | — |
| 2026-02-09 | Kathleen Goin | Chief Operating Officer | A | +48,956 deriv. | — |
| 2026-02-09 | Matthew E Korenberg | CFO, Treasurer | A | +44,123 deriv. | — |
| 2026-02-09 | Jeffrey S Martini | Chief Scientific Officer | A | +64,318 deriv. | — |
| 2026-02-09 | Wes Kaupinen | President and CEO | A | +124,603 deriv. | — |
| 2026-01-23 | Kathleen Goin | Chief Operating Officer | MIXED | — | −$385.10K |
| 2025-12-19 | Kathleen Goin | Chief Operating Officer | MIXED | — | −$380.14K |
| 2025-11-21 | Kathleen Goin | Chief Operating Officer | MIXED | — | −$336.08K |
| 2025-06-11 | Christopher P Kiritsy | Director | A | +12,350 deriv. | — |
| 2025-06-11 | George M Jenkins | Director | A | +12,350 deriv. | — |
| 2025-06-11 | Elaine J Heron | Director | A | +12,350 deriv. | — |
| 2025-06-11 | Todd C Davis | Director | A | +12,350 deriv. | — |
| 2025-06-11 | Tadd S. Wessel | Director | A | +12,350 deriv. | — |
| 2025-06-03 | Ashley Hartmann Kline | Chief Commercial Officer | A | +128,932 deriv. | — |
| 2025-04-10 | George M Jenkins | Director | Buy | +4,990 | +$100.80K |
| 2025-02-10 | Jeffrey S Martini | Chief Scientific Officer | A | +128,932 deriv. | — |
| 2025-02-10 | Matthew E Korenberg | CFO and Treasurer | A | +128,932 deriv. | — |
| 2025-02-10 | Wes Kaupinen | President and CEO | A | +243,831 deriv. | — |
| 2025-02-10 | Kathleen Goin | Chief Operating Officer | A | +128,932 deriv. | — |
| 2025-02-07 | PALVELLA THERAPEUTICS, INC. | CFO and Treasurer | A | +128,932 deriv. | — |
| 2025-02-07 | PALVELLA THERAPEUTICS, INC. | Chief Operating Officer | A | +128,932 deriv. | — |
| 2025-02-07 | PALVELLA THERAPEUTICS, INC. | President and CEO | A | +243,831 deriv. | — |
| 2025-02-07 | PALVELLA THERAPEUTICS, INC. | Chief Scientific Officer | A | +128,932 deriv. | — |
| 2024-12-19 | George M Jenkins | Director | Buy | +4,000 | +$51.72K |
| 2024-12-17 | Matthew E Korenberg | CFO, Treasurer | A | +167,100 deriv. | — |
| 2024-12-17 | Jeffrey S Martini | Chief Scientific Officer | A | +126,416 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| BVF PARTNERS L P/IL | — | 282,223 | $49.37M |
| George M Jenkins | Director | 154,228 | $26.98M |
| Elaine J Heron | Director | 53,691 | $9.39M |
| Kathleen Goin | Chief Operating Officer | 2,270 | $397.08K |
| Matthew E Korenberg | CFO, Treasurer | 1,000 | $174.93K |
| Christopher P Kiritsy | Director | 250 | $43.73K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the PVLA quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.